Provided by Tiger Fintech (Singapore) Pte. Ltd.

REVVITY INC

94.86
+1.841.98%
Pre-market: 94.860.00000.00%08:02 EDT
Volume:2.42M
Turnover:227.06M
Market Cap:11.40B
PE:43.18
High:95.46
Open:94.03
Low:91.75
Close:93.02
Loading ...

Revvity Inc. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains

Dow Jones
·
12 Apr

KeyBanc Lowers Price Target on Revvity to $135 From $145

MT Newswires Live
·
12 Apr

Bernstein Sticks to Their Hold Rating for Revvity (RVTY)

TIPRANKS
·
11 Apr

Revvity Is Maintained at Overweight by Barclays

Dow Jones
·
10 Apr

Revvity price target lowered to $110 from $140 at Barclays

TIPRANKS
·
10 Apr

This fund manager isn't big on 'Mag 7' tech stocks. But he likes these 'Mag 2.'

Dow Jones
·
10 Apr

KeyBanc Adjusts Price Target on Revvity to $145 From $135, Keeps Overweight Rating

MT Newswires Live
·
09 Apr

KeyBanc Keeps Their Buy Rating on Revvity (RVTY)

TIPRANKS
·
09 Apr

Revvity Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
09 Apr

Revvity Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
08 Apr

Press Release: Revvity to Hold Earnings Call on Monday, April 28, 2025

Dow Jones
·
03 Apr

Revvity Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
03 Apr

Evercore ISI Adjusts Revvity Price Target to $125 From $138, Maintains Outperform Rating

MT Newswires Live
·
02 Apr

Revvity Says FDA Approves Auto-Pure 2400 Liquid Handler for Tuberculosis Test

MT Newswires Live
·
02 Apr

Revvity announces FDA approval for Auto-Pure 2400 liquid handling platform

TIPRANKS
·
02 Apr

BRIEF-Revvity Secures FDA Approval For Improved Automated Latent Tuberculosis Test

Reuters
·
02 Apr

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

THOMSON REUTERS
·
02 Apr

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

Business Wire
·
02 Apr

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

Zacks
·
02 Apr

Revvity Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
02 Apr